Diminished drug transport and augmented radiation sensitivity caused by loss of RLIP76.
This study was undertaken to characterize the consequences of Ral-interacting protein (RLIP76)-loss with respect to drug resistance, transport, radiation resistance, and alternative transport mechanisms in mouse embryonic fibroblasts (MEFs). MEFs were derived from RLIP76+/+, RLIP76+/- and RLIP76-/- mice. The transport of doxorubicin (DOX), colchicine (COL), leukotriene C4 and dinitrophenyl S-glutathione (DNP-SG) was analyzed in inside-out vesicles (IOVs) prepared from MEFs. We used immuno-titration of transport activity to determine the contribution of RLIP76, MRP1, and p-glycoprotein (Pgp) towards total transport activity. Loss of RLIP76 alleles resulted in significant sensitization to radiation, DOX, cisplatin, and vinorelbine (VRL). In IOVs prepared from MEFs, we observed a stepwise loss of transport activity. Loss of RLIP76 confers sensitivity to xenobiotics and radiation due to the loss of a common transport mechanism for glutathione-electrophile conjugates and xenobiotics.
Singhal
Sharad S
SS
Department of Molecular Biology and Immunology, University of North Texas Health Science Center, 3500 Camp Bowie Boulevard, EAD RM No. 542, Fort Worth, TX 76107-2699, United States. ssinghal@hsc.unt.edu
Yadav
Sushma
S
Singhal
Jyotsana
J
Sahu
Mukesh
M
Sehrawat
Archana
A
Awasthi
Sanjay
S
D000477:Alkylating Agents / Q000378:metabolism / Q000633:toxicity; D000818:Animals; D018943:Anthracyclines / Q000378:metabolism / Q000633:toxicity; D001692:Biological Transport / Q000235:genetics; D004317:Doxorubicin / Q000378:metabolism / Q000633:toxicity; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D004705:Endocytosis / Q000235:genetics; D020690:GTPase-Activating Proteins / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D007328:Insulin / Q000378:metabolism; D051379:Mice; D008817:Mice, Mutant Strains; D018384:Oxidative Stress; D045663:Quantum Dots; D011836:Radiation Tolerance / Q000235:genetics; D012235:Rhodamines / Q000378:metabolism; D015262:Xenobiotics / Q000378:metabolism* / Q000633:toxicity
D000477:Alkylating Agents; D018943:Anthracyclines; D020690:GTPase-Activating Proteins; D007328:Insulin; C490620:Ralbp1 protein, mouse; D012235:Rhodamines; D015262:Xenobiotics; D004317:Doxorubicin
Biochem Biophys Res Commun. 2006 Sep 22;348(2):722-7
16890208
J Cell Sci. 1999 Mar;112 ( Pt 5):707-18
9973605
Cancer Res. 2005 Jul 15;65(14):6022-8
16024601
Toxicol Appl Pharmacol. 1999 Mar 15;155(3):215-26
10079207
J Clin Invest. 1994 Mar;93(3):958-65
7907606
J Exp Biol. 2004 Aug;207(Pt 18):3221-31
15299043
Biochemistry. 2000 Aug 8;39(31):9327-34
10924126
Biochem Pharmacol. 2005 Aug 1;70(3):481-8
15950949
Cancer Res. 2007 May 1;67(9):4382-9
17483352
Adv Enzymol Relat Areas Mol Biol. 1978;46:383-414
345769
Int J Cancer. 2003 Sep 20;106(5):635-46
12866021
Cancer Res. 2006 Feb 15;66(4):2354-60
16489041
Int J Oncol. 2003 Apr;22(4):713-20
12632060
Int J Cancer. 2004 Dec 20;112(6):934-42
15386349
Invest Radiol. 1986 Nov;21(11):885-90
3536795
Biochemistry. 1997 Jul 15;36(28):8640-8
9214311
J Cell Sci. 2000 Aug;113 ( Pt 16):2837-44
10910768
Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):553-61
18793957
Free Radic Biol Med. 2004 Sep 1;37(5):607-19
15288119
FEBS Lett. 2006 Apr 17;580(9):2258-64
16579994
J Biol Chem. 2008 Jul 11;283(28):19714-29
18474607
J Biol Chem. 2001 Nov 2;276(44):41213-23
11522795
Cancer Res. 2005 Feb 1;65(3):991-8
15705900